ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Ann Thorac Surg 2009;87:693. doi:10.1016/j.athoracsur.2008.12.045
© 2009 The Society of Thoracic Surgeons
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Francis Pagani
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pagani, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pagani, F.
Related Collections
Right arrow Myocardial infarction
Right arrowRelated Article

Original Articles: Adult Cardiac

Invited Commentary

Francis Pagani, MD, PhD

Section of Cardiac Surgery, University of Michigan Health System, Cardiovascular Center—Room 5161, 1500 E Medical Center Dr, SPC #5864, Ann Arbor, MI 48109-5864

(Email: fpagani@umich.edu).

The first 20% of the full text of this article appears below.

Maltais and colleagues [1] have reported an alternative treatment paradigm for postinfarction ventricular septal defect (VSD) using a catheter-based percutaneous closure method with the Amplatzer device (AGA Medical Corp, North Plymouth, MN). They demonstrated an overall mortality of 42% for patients undergoing device closure, which was not significantly different from the cohort of patients treated with surgical closure. The authors should be congratulated for attempting to devise an alternative treatment option to a very difficult surgical problem [2].

Experience with catheter-based methods of closure of a postinfarction VSD is limited and primarily derived from anecdotal case reports. Recently, Holzer and colleagues [3] reported 18 patients (16 with successful device deployment) with a 30-day mortality of 28%. These patients . . . [Full Text of this Article]


Related Article

Postinfarction Ventricular Septal Defects: Towards a New Treatment Algorithm?
Simon Maltais, Reda Ibrahim, Arsène-Joseph Basmadjian, Michel Carrier, Denis Bouchard, Raymond Cartier, Philippe Demers, Martin Ladouceur, Michel Pellerin, and Louis P. Perrault
Ann. Thorac. Surg. 2009 87: 687-692. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2009 by The Society of Thoracic Surgeons.